Risk assessment in fever and neutropenia in children with cancer: What did we learn?

Esther M. te Poele, Wim J. E. Tissing, Willem A. Kamps, Eveline S. J. M. de Bont*

*Corresponding author voor dit werk

Onderzoeksoutputpeer review

31 Citaten (Scopus)

Samenvatting

Children with cancer treated with chemotherapy are susceptible to bacterial infections and serious infectious complications. However, fever and neutropenia can also result from other causes, for which no antibiotic treatment is needed. In the past decades attempts have been made to stratify the heterogeneous group of pediatric cancer patients with fever and neutropenia into high- and low-fisk groups for bacterial infections or infectious complications. Strategies for risk assessment have resulted in treatment regimens with early discharge or even no hospital admission at all, and/or treatment with oral or no antibiotics. We will provide a historical overview of the changing approach to low-risk fever and neutropenia, and we will also try to identify clear and objective parameters for risk assessment strategies and illustrate their relationship to innate immunity. In the future, new insights into genetic susceptibility on neutropenic fever might be of use in children with cancer with fever and neutropenia. (C) 2008 Elsevier Ireland Ltd. All fights reserved.

Originele taal-2English
Pagina's (van-tot)45-55
Aantal pagina's11
TijdschriftCritical Reviews in Oncology/Hematology
Volume72
Nummer van het tijdschrift1
DOI's
StatusPublished - okt.-2009

Vingerafdruk

Duik in de onderzoeksthema's van 'Risk assessment in fever and neutropenia in children with cancer: What did we learn?'. Samen vormen ze een unieke vingerafdruk.

Citeer dit